Randomized, Placebo-Controlled Study of Tolcapone in Patients With Fluctuating Parkinson Disease Treated With Levodopa-Carbidopa
Open Access
- 1 August 1998
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 55 (8) , 1089-1095
- https://doi.org/10.1001/archneur.55.8.1089
Abstract
TOLCAPONE (3,4-dihydrox-4‘-methyl-5-nitrobenzo-phenone) is a selective and reversible catechol-O-methyltransferase inhibitor1 that is being developed as adjunctive therapy to levodopa plus a peripheral dopa decarboxylase inhibitor (benserazide or carbidopa) in the treatment of Parkinson disease.Keywords
This publication has 5 references indexed in Scilit:
- Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trialNeurology, 1997
- Pharmacokinetic‐pharmacodynamic interaction between the COMT inhibitor tolcapone and single‐dose levodopa.British Journal of Clinical Pharmacology, 1995
- Acute Effects of COMT Inhibition on L-DOPA Pharmacokinetics in Patients Treated with Carbidopa and SelegilineClinical Neuropharmacology, 1995
- Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-DOPA and dopamine in ratsEuropean Journal of Pharmacology, 1995
- The Sickness Impact Profile: Development and Final Revision of a Health Status MeasureMedical Care, 1981